Related Experiment Video
Updated: May 25, 2026

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method
Published on: October 23, 2018
Association of metabolic vulnerability index with various chronic liver diseases and mortality: a large prospective
Zihan Qin1, Kaiqi Yang1, Zheng Liang1
1Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University; State Key Laboratory of Digestive Health; National Clinical Research Center for Digestive Disease; Beijing Key Laboratory of Early Gastrointestinal Cancer Medicine and Medical Devices, 100050, Beijing, China.
Background:
The association between metabolic vulnerability index (MVX), a composite biomarker integrating inflammatory and metabolic pathways, and chronic liver diseases (CLDs) is still unclear.
Methods:
This prospective cohort study included 255,171 participants from the UK Biobank, with a median follow-up period of 13.71 years. Multivariable-adjusted cox proportional hazards models, restricted cubic splines (RCS) and sensitivity analyses were used to evaluate the association between MVX and CLDs.
Results:
This study showed that higher levels of MVX (Q4 vs Q1) significantly increased the risk of CLDs after adjusted by socio-demographic and health status factors (all P < 0.05): cirrhosis (HR = 1.60, 95%CI:1.38-1.86), alcoholic-related liver disease (HR = 1.34, 95%CI:1.07-1.68), autoimmune liver disease (HR = 1.35, 95%CI:1.12-1.62), liver and biliary tract cancer (HR = 1.32, 95%CI:1.05-1.66), liver disease-related death (HR = 2.11, 95%CI:1.59-2.80), and all-cause mortality (HR = 1.17, 95%CI:1.13-1.21). No association was found between MVX and viral hepatitis. RCS and threshold analysis showed a reverse L-shaped association between MVX and cirrhosis and liver-related deaths, a linearly increasing association with AILD and LBC, and a J-shaped association with ALD and all-cause mortality. Subgroups analysis and sensitivity analyses demonstrated stable correlation between MVX and CLDs and death events.
Conclusion:
MVX is a promising indicator for independently predicting CLD events, liver-related mortality, and all-cause mortality. As a marker of metabolic-inflammatory dysregulation, MVX may enable early identification of high-risk individuals for targeted primary prevention of CLDs.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Cirrhosis I: Introduction
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Cirrhosis II: Pathophysiology